Cargando…

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC

Shedding of the human NKG2D ligand MIC (MHC class I-chain-related molecule) from tumor cell surfaces correlates with progression of many epithelial cancers. Shedding-derived soluble MIC (sMIC) enables tumor immune escape through multiple immune suppressive mechanisms, such as disturbing natural kill...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basher, Fahmin, Jeng, Emily K., Wong, Hing, Wu, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808035/ https://www.ncbi.nlm.nih.gov/pubmed/26625316

Ejemplares similares

Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation
por: Dhar, Payal, et al.
Publicado: (2021)

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
por: Basher, Fahmin, et al.
Publicado: (2020)

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy
por: Zhang, Jinyu, et al.
Publicado: (2019)

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
por: Zhang, Jinyu, et al.
Publicado: (2015)

The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
por: Wong, Hing C, et al.
Publicado: (2013)

CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
por: Margolin, Kim, et al.
Publicado: (2014)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas
por: Rosario, Maximillian, et al.
Publicado: (2014)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells
por: Fantini, Massimo, et al.
Publicado: (2019)

Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
por: Chen, Xiaoyue, et al.
Publicado: (2015)

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model
por: Furuya, Hideki, et al.
Publicado: (2019)

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
por: Kim, Peter S., et al.
Publicado: (2016)

Intracellular Sequestration of the NKG2D Ligand MIC B by Species F Adenovirus
por: Oliveira, Edson R. A., et al.
Publicado: (2021)

IL-15 and N-803 for HIV Cure Approaches
por: Howard, J. Natalie, et al.
Publicado: (2023)

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies
por: Lui, Grace, et al.
Publicado: (2023)

ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
por: Chen, Wujun, et al.
Publicado: (2022)

Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection
por: Harwood, Olivia, et al.
Publicado: (2021)

Soluble NKG2D ligands impair CD8(+) T cell antitumor function dependent of NKG2D downregulation in neuroblastoma
por: Zhang, Yi, et al.
Publicado: (2023)

Oktett, D. 803
por: Schubert, Franz, 1797-1828
Publicado: (1988)

Levels of Soluble NKG2D Ligands and Cancer History in Patients Starting Hemodialysis
por: Nagai, Kei, et al.
Publicado: (2022)

Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion
por: Gomes-Giacoia, Evan, et al.
Publicado: (2014)

Colorectal cancer with Synchronous liver-limited Metastases: the protocol of an Inception Cohort study (CoSMIC)
por: Siriwardena, Ajith K, et al.
Publicado: (2017)

Soluble Ligands for the NKG2D Receptor Are Released during Endometriosis and Correlate with Disease Severity
por: González-Foruria, Iñaki, et al.
Publicado: (2015)

Schedule of experiment R803
por: Jarlskog, G
Publicado: (1973)

MIC26 and MIC27 cooperate to regulate cardiolipin levels and the landscape of OXPHOS complexes
por: Anand, Ruchika, et al.
Publicado: (2020)

Oktett F-Dur, D. 803= octet in F major D 803
por: Schubert, Franz 1797-1828
Publicado: (2014)

Genomic screening methodology not requiring barcoding: Single nucleotide polymorphism-based, mixed-cell screening (SMICS)
por: Zhang, Zhuwei, et al.
Publicado: (2023)

Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype
por: Xiao, Gang, et al.
Publicado: (2015)

The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer
por: Tan, Ge, et al.
Publicado: (2023)

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation
por: Vyas, Maulik, et al.
Publicado: (2017)

Octets D. 803 , D. 72
por: Schubert, Franz, 1797-1828
Publicado: (1993)

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study
por: Drusbosky, Leylah, et al.
Publicado: (2020)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
por: Frazao, Alexandra, et al.
Publicado: (2019)

Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma
por: Cox, Steven T., et al.
Publicado: (2018)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
por: Zöller, Tobias, et al.
Publicado: (2018)

Unusual Presentation of Renal Medullary Carcinoma With Undiagnosed Sickle Cell Trait
por: Basher, Fahmin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_olirq1houoqearctkq8drj3v8c